Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody designed to specifically target the spike glycoprotein of SARS-CoV-2. This antibody exhibits high affinity binding to the receptor-binding domain (RBD) of the recombinant spike protein, demonstrated by an equilibrium dissociation constant (Kd) of 0.21 nM and an effective concentration (EC50) of 14.9 ng/mL. These properties suggest that Beludavimab is highly effective in binding to the spike protein, potentially inhibiting the virus's ability to enter host cells and proliferate. This antibody is a valuable tool for research focused on the mechanisms of SARS-CoV-2 infection and the development of therapeutic strategies.
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody designed to specifically target the spike glycoprotein of SARS-CoV-2. This antibody exhibits high affinity binding to the receptor-binding domain (RBD) of the recombinant spike protein, demonstrated by an equilibrium dissociation constant (Kd) of 0.21 nM and an effective concentration (EC50) of 14.9 ng/mL. These properties suggest that Beludavimab is highly effective in binding to the spike protein, potentially inhibiting the virus's ability to enter host cells and proliferate. This antibody is a valuable tool for research focused on the mechanisms of SARS-CoV-2 infection and the development of therapeutic strategies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
